A modelled economic evaluation comparing atomoxetine with methylphenidate in the treatment of children with attention-deficit/hyperactivity disorder in Spain

Jihyung Hong; Dilla, Tatiana; Arellano, Jorge
January 2009
BMC Psychiatry;2009, Vol. 9, Special section p1
Academic Journal
Background: Attention Deficit/Hyperactivity Disorder (ADHD) is a neurobehavioural disorder, affecting 3-6% of school age children and adolescents in Spain. Methylphenidate (MPH), a mild stimulant, had long been the only approved medication available for ADHD children in Spain. Atomoxetine is a non-stimulant alternative in the treatment of ADHD with once-a-day oral dosing. This study aims to estimate the cost-effectiveness of atomoxetine compared to MPH. In addition, atomoxetine is compared to 'no medication' for patient populations who are ineligible for MPH (i.e. having stimulant-failure experience or co-morbidities precluding stimulant medication). Methods: An economic model with Markov processes was developed to estimate the costs and benefits of atomoxetine versus either MPH or 'no medication'. The incremental cost per quality-adjusted life-year (QALY) was calculated for atomoxetine relative to the comparators. The Markov process incorporated 14 health states, representing a range of outcomes associated with treatment options. Utility values were obtained from the utility valuation survey of 83 parents of children with ADHD. The clinical data were based on a thorough review of controlled clinical trials and other clinical literature, and validated by international experts. Costs and outcomes were estimated using Monte Carlo simulation over a 1-year duration, with costs estimated from the perspective of the National Health Service in Spain. Results: For stimulant-naïve patients without contra-indications to stimulants, the incremental costs per QALY gained for atomoxetine were € 34 308 (compared to an immediate-release MPH) and € 24 310 (compared to an extended-release MPH). For those patients who have stimulant-failure experience or contra-indications to stimulants, the incremental costs per QALY gained of atomoxetine compared to 'no medication' were € 23 820 and € 23 323, respectively. Conclusion: The economic evaluation showed that atomoxetine is an effective alternative across a range of ADHD populations and offers value-for money in the treatment of ADHD.


Related Articles

  • Mental health.  // Archives of Disease in Childhood;Apr2006 Supplement, Vol. 91, pA39 

    The article presents abstracts of medical research. They include "Re-Audit of Management of ADHD With Methylphenidate Based on Nice Guidance," "ADHD: Collaborative Between Paediatricians and CAMHS. Does it Work?" and "A Transitional and Adult Service for Patients With ADHD. Responding to the NSF."

  • Just say yes to Ritalin! Diller, Lawrence H. // Human Life Review;Winter2001, Vol. 27 Issue 1, p108 

    Focuses on pressures in the United States to use Ritalin to treat school children with attention deficit hyperactivity disorder. Need to explore other options; Prerequisites to prescribing Ritalin; Concerns over Surgeon General David Satcher's statement about Ritalin being underprescribed.

  • Effects of methylphenidate on the academic performance of children with attention-deficit... Carlson, Caryn L.; Bunner, Melissa R. // School Psychology Review;1993, Vol. 22 Issue 2, p184 

    Investigates the effects of psychostimulant medications on learning and achievement in children with attention-deficit hyperactivity disorder. Short- and long-term effects of methylphenidate; Individual differences in response to medication.

  • The impact of recent lawsuits on methylphenidate sales. Safer, Daniel J. // Clinical Pediatrics;Mar1994, Vol. 33 Issue 3, p166 

    Focuses on the impact of lawsuits concerning alleged misuse of methylphenidate (Ritalin) treatment for hyperactivity in children. Background information; Effect on sales; Examination of government records and estimated sales; Media campaign by various groups; Intimidating aspects of lawsuits.

  • Ritalin may influence serotonin balance in hyperactive children. Berger, Abi // BMJ: British Medical Journal (International Edition);01/23/99, Vol. 318 Issue 7178, p212 

    Discusses how methylphenidate or Ritalin may influence serotonin balance in hyperactive children. Effect of the drug in children with attention deficit hyperactivity disorder (ADHD); Result of the research on the effectiveness of the drug.

  • Out of Control? Sinha, Gunjan // Popular Science;Jun2001, Vol. 258 Issue 6, p48 

    Presents views on whether the drug Ritalin helps in treating children with attention deficit hyperactivity disorder (ADHD). How doctors make diagnosis for the disorder; Mechanism of the drug in the human brain; Results of a study which compared the educational outcomes of ADHD children with that...

  • Danish Medicines Agency reports on safety of methylphenidate.  // Reactions Weekly;11/20/2010, Issue 1328, p2 

    The article deals with the warning issued by the Danish Medicines Agency about the use of methylphenidate in adults with attention-deficit hyperactivity disorder (ADHD).

  • Quillivant XR Available.  // Nurse Practitioners Prescribing Reference;Spring2013, Vol. 20 Issue 1, pA-19 

    The article offers information on Quillivant XR from Pfizer, which is available to treat Attention-Deficit Hyperactivity Disorder (ADHD) in patients less than or equal to 6 years old.

  • How to fix Tom Sawyer. Donnelly, Patrick // Alberta Report / Newsmagazine;06/15/98, Vol. 25 Issue 26, p32 

    Describes the prevalence of Ritalin in treating North American children. Number of children diagnosed with attention-deficit disorder (ADD) and given Ritalin; Anti-Ritalin backlash; Comments from David Cohen, University of Montreal; Details about the drug; Views of Thomas Millar, child...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics